New shot targets hidden heart risk factor
NCT ID NCT07172646
Summary
This early-stage study is testing a new injectable drug called SRSD216 in people with high levels of lipoprotein(a), a type of fat in the blood linked to heart disease risk. The main goals are to check if the drug is safe and well-tolerated, and to see how it affects lipoprotein(a) levels. Researchers will test different doses in 84 participants to find the right amount for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPOPROTEINEMIA (A) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.